Sharps Technology, Inc. Secures $3.5 Million in Bridge Financing
Sharps Technology, Inc. (NASDAQ: STSS), a rising name in the field of innovative medical devices and pharmaceutical packaging, has successfully secured around $3.5 million in bridge financing. This financing highlights the company’s dedication to developing advanced syringe products that prioritize safety and efficiency.
Overview of the Bridge Financing
This financing was accomplished through a securities sale, where investors received approximately $1,250 in secured notes along with shares of common stock for every $1,000 invested. The total gross proceeds reached $4,375,000 in principal and included over 5.7 million shares of common stock allocated to investors. Notably, this funding round did not include any pre-funded warrants.
Intended Use of Funds
The funds raised will be used for general corporate purposes and working capital needs. Sharps Technology plans to use this funding to boost operational efficiency and advance product development, aligning with its mission to promote safety in healthcare.
Involvement of Key Participants
Aegis Capital Corp. acted as the exclusive placement agent for this private placement. Additionally, legal support was provided by Sichenzia Ross Ference Carmel LLP for Sharps Technology and by Kaufman & Canoles, P.C. for the placement agent. Such collaborations are essential for navigating the challenges of funding in the medical device industry.
About the Company
Sharps Technology stands out for its innovative medical devices, particularly its patented smart-safety syringe products designed to meet healthcare demands. The company emphasizes producing syringes that minimize waste while integrating both passive and active safety features. Moreover, Sharps offers specialized products utilizing copolymer technology, enhancing its position in the prefillable syringe market.
Manufacturing and Partnering Strategies
The company operates a manufacturing facility in Hungary and is actively engaged in a key partnership with Nephron Pharmaceuticals. This collaboration aims to significantly upgrade Sharps Technology’s manufacturing capabilities in the U.S., allowing the company to meet the rising demand for its innovative products more effectively.
Outlook for the Future
With this recent funding, Sharps Technology, Inc. is in a great position to broaden its product range and seek new growth opportunities. As the healthcare industry places greater emphasis on safety and efficiency, Sharps’ commitment to innovation and security should position it well for upcoming success.
Dedication to Safety
At the core of the company’s philosophy is the goal of creating safer healthcare solutions. By concentrating on innovative syringe technologies, Sharps Technology continually strives to enhance medical outcomes and alleviate potential risks involved in medical procedures.
Frequently Asked Questions
What is the purpose of the $3.5 million bridge financing?
The funds from the bridge financing are designated for general corporate activities and working capital needs at Sharps Technology.
Who was the placement agent for this financing?
Aegis Capital Corp. acted as the exclusive placement agent for the bridge financing.
What type of products does Sharps Technology focus on?
Sharps Technology specializes in innovative medical devices, especially smart-safety syringe products that enhance safety and minimize waste in healthcare settings.
How is Sharps Technology improving its manufacturing capacity?
The partnership with Nephron Pharmaceuticals enables Sharps Technology to significantly enhance its manufacturing capabilities in the United States.
What safety features are included in Sharps syringes?
Sharps syringes come with both passive and active safety features to reduce risks and encourage safer medical practices.
